| Typicality: | 0.605 |
| Saliency: | 0.555 |
| for prevention | 168 | purpose |
| for mitigation | 62 | purpose |
| in april | 7 | temporal |
| product → be approved by → the fda | 301 |
| product → be approved by → fda | 80 |
| product → be authorized by → fda | 58 |
| product → be → fda-approved | 54 |
| negative | neutral | positive |
| 0.202 | 0.439 | 0.360 |
| Raw frequency | 493 |
| Normalized frequency | 0.555 |
| Modifier score | 0.864 |
| Perplexity | 35.572 |